By Fineline Cube 
Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced today that the first patient has been successfully dosed in a Phase 1b/II clinical trial (NCT07099430) evaluating Opamtistomig (LBL-024), a PD-L1/4-1BB bispecific antibody, as monotherapy or in combination with other agents for the first-line treatment of advanced melanoma.
Drug Mechanism and Potential
Opamtistomig is a uniquely designed PD-L1/4-1BB bispecific antibody that simultaneously blocks PD-1/L1-mediated immune suppression and enhances 4-1BB-regulated T-cell activation. This dual mechanism has the potential to convert “cold tumors” into “hot tumors,” overcoming resistance to immunotherapy and improving response rates in hard-to-treat cancers.
Clinical Development
Previously, multiple studies have been initiated to evaluate Opamtistomig in extrapulmonary neuroendocrine carcinoma (EP-NEC), first-line small cell lung cancer (SCLC), and first-and second-line non-small cell lung cancer (NSCLC).-Fineline Info & Tech